Joele Frank is handling media for Alder BioPharmaceuticals, which is focused on the development and commercialization of migraine treatments, in its $2B sale to Denmark’s Lundbeck.

The Danish company is offering $18 per-share for Alder, a 79 percent premium over its Sept. 13 closing price on the NASDAQ.

The owner of a portfolio of brain disease therapies will ante up another $2 per-share, if European regulators approve Alder’s next-generation eptinezumab migraine drug. The US Food & Drug Administration is on track to okay the treatment in February.

An estimated 135M people experience migraines annually. They are characterized by recurrent episodes of moderate to severe headaches accompanied by nausea, vomiting and sensitivity to sound and light.

CEO Deborah Dunsire called Alder an excellent strategic fit that leverages Lundbeck’s “specialized commercial expertise in delivering medicines for brain diseases.”

The transaction is expected to wrap up by yearend.

Joele Frank, Wilkinson Brimmer Katcher’s Andy Brimmer, Aura Reinhard and Tanner Kaufman represent Alder, while Stern Investor Relations’ Sarah McCabe works Wall Street for the Bothell, WA-based biopharmaceutical company.